Shakeela Bahadur

745 total citations
8 papers, 174 citations indexed

About

Shakeela Bahadur is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Shakeela Bahadur has authored 8 papers receiving a total of 174 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Immunology. Recurrent topics in Shakeela Bahadur's work include Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (3 papers) and HER2/EGFR in Cancer Research (3 papers). Shakeela Bahadur is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Advanced Breast Cancer Therapies (3 papers) and HER2/EGFR in Cancer Research (3 papers). Shakeela Bahadur collaborates with scholars based in United States, Italy and South Korea. Shakeela Bahadur's co-authors include Lida A. Mina, Francine Chen, Edwin P. Rock, David Riseberg, Sam Pyo Hong, Javier Cortés, William J. Gradishar, Michelino De Laurentiis, Fátima Cardoso and Mark D. Pegram and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shakeela Bahadur

8 papers receiving 173 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shakeela Bahadur United States 6 144 54 54 38 26 8 174
Rebecca Ibrahim France 5 106 0.7× 39 0.7× 19 0.4× 32 0.8× 25 1.0× 10 141
Jeannette Dinin United States 2 93 0.6× 49 0.9× 16 0.3× 26 0.7× 34 1.3× 2 128
Kit Fuhrman United States 4 95 0.7× 22 0.4× 41 0.8× 31 0.8× 55 2.1× 8 153
Haiyi Deng China 10 172 1.2× 22 0.4× 24 0.4× 151 4.0× 34 1.3× 33 246
Gert Van den Eyden Belgium 4 133 0.9× 21 0.4× 108 2.0× 27 0.7× 31 1.2× 4 193
Mohammad Atiq United States 6 88 0.6× 12 0.2× 49 0.9× 64 1.7× 54 2.1× 21 155
Mojca Unk Slovenia 6 134 0.9× 69 1.3× 15 0.3× 117 3.1× 24 0.9× 14 193
Rinat Yerushalmi Israel 7 139 1.0× 31 0.6× 9 0.2× 67 1.8× 50 1.9× 11 182
Gregory Crane United States 6 162 1.1× 11 0.2× 38 0.7× 70 1.8× 18 0.7× 11 200

Countries citing papers authored by Shakeela Bahadur

Since Specialization
Citations

This map shows the geographic impact of Shakeela Bahadur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shakeela Bahadur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shakeela Bahadur more than expected).

Fields of papers citing papers by Shakeela Bahadur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shakeela Bahadur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shakeela Bahadur. The network helps show where Shakeela Bahadur may publish in the future.

Co-authorship network of co-authors of Shakeela Bahadur

This figure shows the co-authorship network connecting the top 25 collaborators of Shakeela Bahadur. A scholar is included among the top collaborators of Shakeela Bahadur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shakeela Bahadur. Shakeela Bahadur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Curigliano, Giuseppe, Joyce O’Shaughnessy, François‐Clément Bidard, et al.. (2025). Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.. Journal of Clinical Oncology. 43(16_suppl). 1001–1001. 2 indexed citations
2.
Wang, Judy S., Muralidhar Beeram, Pavani Chalasani, et al.. (2023). Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor. Cancer Research. 83(5_Supplement). P4–1. 1 indexed citations
3.
Mina, Lida A., et al.. (2020). <p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p>. Breast Cancer Targets and Therapy. Volume 11. 321–328. 36 indexed citations
4.
Patel, Manish R., Jason J. Luke, Erika Hamilton, et al.. (2020). 313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms. SHILAP Revista de lepidopterología. A193.1–A193. 6 indexed citations
5.
Wang, Jie, Adam S. Asch, Nada Hamad, et al.. (2020). A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 21–22. 19 indexed citations
6.
Im, Seock‐Ah, Fátima Cardoso, Javier Cortés, et al.. (2020). SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. Journal of Clinical Oncology. 38(15_suppl). 1040–1040. 5 indexed citations
7.
Luke, Jason J., Manish R. Patel, Erika Hamilton, et al.. (2020). A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology. 38(15_suppl). 3004–3004. 43 indexed citations
8.
Rugo, Hope S., Seock‐Ah Im, Santiago Escrivá-de-Romaní, et al.. (2019). SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. Journal of Clinical Oncology. 37(15_suppl). 1000–1000. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Ibrahim Breakdown of academic impact, for papers by Jeannette Dinin Breakdown of academic impact, for papers by Kit Fuhrman Breakdown of academic impact, for papers by Haiyi Deng Breakdown of academic impact, for papers by Gert Van den Eyden Breakdown of academic impact, for papers by Mohammad Atiq Breakdown of academic impact, for papers by Mojca Unk Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Gregory Crane
Rankless by CCL
2026